PRSS2Biomarker1 paper studies itHuman trial1LatestENDO 2025 Abstract·Oct 23OR09-07 Dynamic Proteomic Profiling in a 5-week Crossover Trial of Liraglutide in Obesity Reveals Weight-Dependent Myostatin Downregulation and Multi-Pathway Effects Beyond Weight ReductionRandomized trial in 20 peopleLiraglutidePaper
ENDO 2025 Abstract·Oct 23OR09-07 Dynamic Proteomic Profiling in a 5-week Crossover Trial of Liraglutide in Obesity Reveals Weight-Dependent Myostatin Downregulation and Multi-Pathway Effects Beyond Weight ReductionRandomized trial in 20 peopleLiraglutidePaper